毕得医药：七名股东计划减持不超过1%公司股份

Group 1 - The core point of the news is that shareholders of Bid Pharma plan to reduce their holdings due to personal liquidity needs, with a total reduction not exceeding 1% of the company's total share capital [1] - Specific reduction details include: Li Yijing plans to reduce up to approximately 227,900 shares (0.25% of total share capital), Chen Jun up to approximately 136,400 shares (0.15%), Li Li up to approximately 136,400 shares (0.15%), Du Juan up to approximately 136,400 shares (0.15%), Li Aifei up to approximately 131,800 shares (0.15%), Geng Yong up to approximately 91,300 shares (0.1%), and Jiang Yamei up to approximately 48,000 shares (0.05%) [1] - The reduction price will be determined based on the market price at the time of the actual implementation [1] Group 2 - For the year 2024, Bid Pharma's revenue composition is entirely from the research and experimental development industry, accounting for 100% [2] - As of the latest report, Bid Pharma has a market capitalization of 6.4 billion yuan [3]